作　　者： (冯健）; (张煜）; (曹华明）;

机构地区： 无锡市人民医院心内科,江苏无锡214023

出　　处： 《海南医学院学报》 2017年第13期1752-1754,1758,共4页

摘　　要： 目的:探讨瑞舒伐他汀对慢性心力衰竭患者炎性因子、氧化应激及心功能的影响。方法:选取2015年7月~2016年12月我院收治的慢性心力衰竭患者200例,随机分为观察组100例和对照组100例,两组患者均接受慢性心衰的常规治疗,观察组在此基础上服用瑞舒伐他汀,比较两组治疗前后的白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、超氧化物歧化酶(SOD)、丙二醛(MDA)及心功能指标。结果:观察组治疗后的IL-6、TNF-α、hs-CRP水平均低于治疗前,且低于治疗后的对照组,差异有统计学意义(P<0.05);对照组治疗后的IL-6、TNF-α、hs-CRP水平与治疗前相比无显著差异(P>0.05)。观察组治疗后的SOD水平为(172.71±5.22)U/mL,高于治疗前(P<0.05),且高于治疗后的对照组(P<0.05);观察组治疗后的MDA水平为(3.99±0.31)nmol/mL,低于治疗前(P<0.05),且低于治疗后的对照组(P<0.05);对照组治疗后的SOD、MDA水平与治疗前相比差异无统计学意义(P>0.05)。治疗后,两组患者的左室舒张末期容积(LVEDD)、左室收缩末期容积(LVESD)分别为(52.19±1.33)、(36.33±2.82)mm和(59.88±1.62)、(42.41±3.43)mm,均较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组患者的左室射血分数(LVEF)分别为(49.90±6.26)%、(42.72±5.14)%,均较治疗前升高,且观察组高于对照组,差异有统计学意义(P<0.05)。结论:瑞舒伐他汀可有效抑制慢性心力衰竭患者的炎性因子及氧化应激反应,并能够促进心功能改善。 Objective：To explore the effect of rosuvastatin on inflammatory factor,oxidative stress and cardiac function in patients with chronic heart failure.Methods：A total of 200 cases of patients with chronic heart failure who were admitted in our hospital from July 2015 to December 2016 were selected and were divided randomly into observation group（100cases）and control group（100cases）,patients of both groups were given conventional treatment of chronic heart failure,and observation group was given rosuvastatin on this basis.Interleukin-6（IL-6）,tumor necrosis factor-α（TNF-α）,hypersensitivity-C reaction protein（hs-CRP）,superoxidedismutase（SOD）,malondialdehyde（MDA）and cardiac function before and after treatment in two groups are compared.Results：IL-6,TNF-α,hs-CRP level after treatment was lower than before treatment in observation group and also lower than after treatment in control group.The difference was significant（P〈0.05）;IL-6,TNF-α,hsCRP level after treatment was of no significant difference,compared with before treatment in control group（P〈0.05）.SOD level was（172.71±5.22）U/mL after treatment in observation group,significantly higher than before treatment（P〈0.05）,moreover significantly higher than after treatment in control group（P〈0.05）;MDA level was（3.99±0.31）nmol/mL after treatment in observation group,significantly lower than before treatment（P〈0.05）,moreover significantly lower than after treatment in control group（P〈0.05）;there was no significant difference in SOD,MDA level between before and after treatment in control group（P〈0.05）.After treatment,LVEDD,LVEDF were（52.19±1.33）mm,（36.33±2.82）mm,（59.88±1.62）mm,（42.41±3.43）mm in both groups,all were lower than before treatment,and observation group was lower than control group,there was statistical significant difference（P〈0.05）;LVEF of two groups was（49.90±6.26）%,（42.72±5.14）% respectively after treatment,higher than before treatment,and

关 键 词： 瑞舒伐他汀 慢性心力衰竭 炎性因子 氧化应激 心功能